

## REMARKS

Reconsideration and reexamination is respectfully requested. The indication of allowable subject matter is acknowledged with appreciation. Claim 6 has been amended to correct a minor typographical error therein. The amendment does not alter the scope of the claim.

Claims 1-19 were rejected under Section 112, first paragraph because the Office Action states that the specification does not reasonably provide enablement for making solvates. While not agreeing with this rejection, and solely to expedite prosecution of the application, claim 1 has been amended.

Claim 16 was rejection under Section 112, first paragraph, because, the Office Action states, that the specification does not reasonably provide enablement for making a prodrug of the claimed compounds. Additionally, claim 16 was rejected under Section 112, second paragraph. While not agreeing with the rejections, and solely to expedite prosecution of the application, claim 16 has been amended. Therefore, withdrawal of the Section 112 rejections are respectfully requested.

Claims 1-5 and 16 were rejected under Section 103 as being unpatentable over Ikesu et al. Applicants assert that the obviousness rejection is inappropriate as the compounds useful for a pharmaceutical application and pharmaceutical compositions are not rendered obvious by compounds useful as a photographic coupler. Nonetheless, in order to expedite prosecution of this application, claim 1 has been amended such the R<sup>1</sup> cannot be hydrogen. Because Ikesu et al does not teach nor render obvious compounds having a substituent at that position, withdrawal of the Section 103 rejection is respectfully requested.

Upon a finding of allowability of the compound claims, applicants request rejoinder of the method of use claims.

The application is now believed to be in condition for allowance and an indication thereof is respectfully requested. The examiner is welcomed to call Applicant's representative if he feels a telephone interview would further prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
Phone: 609-252-4379  
Date: April 19, 2007

/mary k vanatten/  
Mary K. VanAtten  
Attorney for Applicant  
Reg. No. 39,408